Item 2.02 Results of Operations and Financial Condition.
On May 14, 2024, the Company issued a press release announcing its financial results for its fiscal quarter ended March 31, 2024 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 8.01 Other Events.
The Press Release discussed that the Company concluded its Phase 2 clinical trial of stenoparib early due to clear clinical benefits observed, including tumor shrinkage and long-term disease stability, in heavily pre-treated ovarian cancer patients. Using the Company’s DRP® companion diagnostic to pre-screen patients, the trial targeted those most likely to benefit. The promising results have provided sufficient proof of concept, prompting the Company to halt enrollment with the purpose of preparing a follow-on trial with FDA regulatory intent.